Categories: News

Allogene Therapeutics to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 12:45 p.m. Pacific Time/3:45 p.m. Eastern Time.

A live webcast of the presentation will be made available on the Company’s website at www.allogene.com under the Investors tab in the News and Events section. Following the live audio webcast, a replay will be available on the Company’s website for approximately 30 days.

About Allogene Therapeutics
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements for Allogene
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop allogeneic CAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the SEC, including without limitation in its Form 10-Q for the quarter ended September 30, 2021. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:
Christine Cassiano
Chief Communications Officer
(714) 552-0326
Christine.Cassiano@allogene.com

Staff

Recent Posts

RaySearch releases RayStation 2024B

STOCKHOLM, July 1, 2024 /PRNewswire/ -- RaySearch Laboratories AB (publ) announces the launch of RayStation®*…

5 mins ago

Dawn Health and Merck are collaborating to support Growth Disorders care

COPENHAGEN, Denmark, July 1, 2024 /PRNewswire/ -- Dawn Health, the digital health company pioneering patient-first innovation,…

5 mins ago

XRP Healthcare: Helping to Transform HIV and AIDS Care with Innovative Prescription Savings Solutions

DUBAI, UAE, July 1, 2024 /PRNewswire/ -- XRP Healthcare has announced a new initiative aimed…

5 mins ago

CBD of Denver Announces June Revenue and Successful Exhibition at Mary Jane Trade Fair in Berlin

Denver, Colorado--(Newsfile Corp. - July 1, 2024) - CBD of Denver, Inc. (OTC Pink: CBDD)…

1 hour ago

Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris

PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 1, 2024 / Biophytis SA (Euronext…

3 hours ago

Transforming Healthcare with AI: YiduTech’s Gong Rujing at Summer Davos

DALIAN, China, June 30, 2024 /PRNewswire/ -- "AI in healthcare is extremely challenging. For companies,…

6 hours ago